Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Hepcidin in Anemic Chronic Heart Failure (CHF) Patients
This study is ongoing, but not recruiting participants.
Sponsored by: Medical University of Vienna
Information provided by: Medical University of Vienna
ClinicalTrials.gov Identifier: NCT00437866
  Purpose

Background: Anemia in chronic heart failure (CHF) is directly linked to increased mortality and reduced exercise capacity. The pathomechanism for the development of anemia in CHF is not well understood. Impairment of iron homeostasis is discussed to be one of the major triggers in anemia of chronic disease. Hepcidin was recently described as the central regulator of iron homeostasis.

Main hypothesis: Plasma hepcidin levels are altered in anemic CHF patients compared to non anemic controls and might be a main contributing factor of anemia in CHF.

Iron regulator-hypothesis High levels of cytokines in CHF patients cause up-regulation of hepcidin, which in turn leads to low iron uptake causing anemia. In this case venous hepcidin and hemoglobin concentrations should both correlate with cytokine levels.

Erythropoietin regulator-hypothesis Dysregulation of the erythropoietin system results in anemia, which represses hepcidin. This leads to a negative correlation between hemoglobin and hepcidin in plasma.

Methods: 100 consecutive patients diagnosed with systolic CHF will be prospectively included in the study. Iron status will be assessed and hepcidin, erythropoietin as well as interleukin-1, interleukin-6 and soluble TNF alpha receptor levels will be measured by ELISA.

Patients will be followed up for one year and mortality, rehospitalization and worsening of CHF will be documented.


Condition
Anemia
Chronic Heart Failure

MedlinePlus related topics: Anemia Heart Failure
U.S. FDA Resources
Study Type: Observational
Study Design: Natural History, Longitudinal, Defined Population, Prospective Study
Official Title: Hepcidin in the Pathogenesis of Anemia in Patients With Chronic Heart Failure

Further study details as provided by Medical University of Vienna:

Study Start Date: January 2007
Estimated Study Completion Date: June 2008
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  1. Systolic left ventricular dysfunction (LVEF<45%)
  2. Signed informed consent

Exclusion Criteria:

  1. Women of child bearing potential
  2. Pregnancy
  3. Non cardiac illness limiting life expectancy to <1 year
  4. Renal disease of non-cardiac reason
  5. Malignancy
  6. Chronic inflammatory disease
  7. Acute infection
  8. Erythropoietin therapy or iron substitution within the last 6 months
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00437866

Locations
Austria, Vienna-Austria
Medical University of Vienna
Vienna, Vienna-Austria, Austria, 1090
Sponsors and Collaborators
Medical University of Vienna
Investigators
Principal Investigator: Martin Huelsmann, MD Medical University of Vienna
  More Information

Study ID Numbers: Version 1.0, 25.11.2006
Study First Received: February 20, 2007
Last Updated: July 16, 2007
ClinicalTrials.gov Identifier: NCT00437866  
Health Authority: Austria: EC of the Medical University of Vienna

Study placed in the following topic categories:
Heart Failure
Heart Diseases
Hematologic Diseases
Anemia

Additional relevant MeSH terms:
Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 15, 2009